Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03584464 · ClinicalTrials.gov registry record · NA
RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)
A NA study, sponsored by Medtronic Vascular.
- Completed
- Registry status
- NA
- Development phase
- 205
- Enrollment target
NCT03584464 is a NA study that has completed, run by Medtronic Vascular. The registered enrollment target is 205 participants.
The verdict
NCT03584464, a NA study, has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 205 participants
- Enrollment target
Study Summary
To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population. To collect data on the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in bifurcated lesions.
Interventions
- DEVICE Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2018-05-14 |
| Est. Completion | 2022-09-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03584464
The ClinicalTrials.gov registry entry for NCT03584464 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Vascular, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System is the first listed.
NCT03584464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03584464 about?
NCT03584464 is a clinical study titled "RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)". To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population. To collect data on the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in bifurcated lesions.
What is the current status of trial NCT03584464?
This trial is currently completed. It is a NA study. The enrollment target is 205 participants. The study started on 2018-05-14. Estimated completion is 2022-09-28.
What interventions are being tested in trial NCT03584464?
The interventions under investigation include: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System (DEVICE).
Who is sponsoring clinical trial NCT03584464?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.